re: Butterfly Sessions Suppository Experience
When it comes to Cannabis suppositories, the most important thing is dialogue.
We were thrilled to see a review of our 1:1 CBD/THC suppository on the Butterfly Sessions blog. Butterfly Sessions provides online personal health coaching and nutritious plant-based recipes. This is our response to a review of our CBD/THC suppository on the Butterfly Sessions website. You can read the suppository review here.
Cannabis suppositories are not a gimmick. They are a delivery system that makes Cannabinoid therapy accessible to a portion of the population that would otherwise not have access.
While refining our suppository, we worked with patients who used them for varying reasons. Some had trouble swallowing or keeping down edible products. For others, the edible products were not absorbed in their digestive tract, and the Cannabinoids were wasted. Others were looking for a direct application of Cannabinoids to the colon, uterus, or pelvic area. More so than other product types, when someone needs a suppository, it is the only method of ingestion that will work for them.
When transitioning into the i502 market, we asked retail stores which of our products they wanted to see available first. Besides the capsules, one of the most requested products was the cannabis suppository. This was not because stores planned to sell boatloads. It was because the people coming into the shops looking for suppositories really wanted them. Often times they could not "just try something else" because the other options had failed to be effective. This aspect of Cannabis suppositories, that they can provide relief to people who otherwise can't find it with Cannabis, makes them a critical part of the conversation.
At The CPC, we look to see where we can push the current boundaries of dialogue.
How can we include more people, more viewpoints, more experiences, more information? How do we educate the public about suppositories? How do we help retail staff feel comfortable suggesting suppositories? How do we help those who use suppositories feel comfortable talking about their experience?
For that, we are so grateful for the product review on the Butterfly Sessions blog. The review is of our 1:1 CBD/THC 10mg suppository (we also manufacture a 4:1 ratio 20mg CBD and 5MG THC).
We humbly acknowledge that a 10mg dose of THC, no matter how bioavailable or how directly applied, is only useful for some. From the Butterfly Sessions perspective, we see a patient who had access - effective medicine at a manageable cost - that was lost in the implementation of "recreational cannabis". She now has not-strong-enough medicine at an unmanageable cost - weak. From 2008-2016 our suppositories were available in 40mg, 80mg, or 120mg doses. The post even mentions 200mg.
How can we create effective products while remaining compliant? Washington's strict 10mg dose limit could be seen as a lesson learned from Colorado's sprint ahead and the serious stumbles (Dowd) (Nicholson). How can we ensure that Cannabis is manageable for first-time users, without taking medicine away from others? (Hint: It's too late, we already did.)
What responsibility does the recreational market have to the medical cannabis community that came before it? Considering that medical cannabis users were and are sick, took the brunt of the risk, faced most of the persecution and stigmatization, changed public opinion, lobbied for policy, and set in motion the events that would result in a recreational market, we would answer, "a lot of responsibility".
What can we do now within the constraints of the i502 market. Here is a detail we dug up from the Washington Administrative Code.
(a) Single serving. A single serving of a marijuana-infused product must not exceed ten milligrams active tetrahydrocannabinol (THC), or Delta 9.
(b) Maximum number of servings. The maximum number of servings in any one single unit of marijuana-infused product meant to be eaten or swallowed is ten servings or one hundred milligrams of active THC, or Delta 9.
Note that the Washington Administrative Code lists the limit as 10mg of active THC. Should we produce a high THC-a suppository? According to this language we would not be limited to 10mg if we are infusing the suppository with THC-a. Like most of cannabinoid pharmacology, there is not definitive literature on the effects of THC-a. We have seen THC-a consumed in raw juiced cannabis leaves, oil extract, and tinctures. From 2011-2016 we manufactured a THC-a tincture at the request of patients managing pain, spasticity, anxiety, and inflammation. We are interested to hear what you think of this idea. We are striving to make wellness with cannabis simple and accessible and that always starts with dialogue.